Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jun 16, 2026 → Oct 2026
See other at-risk trials from Beijing Inno Medicine Co., Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 6 more changesShow less
    • Primary completion pushed from Jun 16, 2026 to Oct 2026
    • Study sites: 0 to 1
    • Study completion date: Nov 14, 2026 to Dec 2026
    • Start date changed from estimate of Jan 31, 2026 to Feb 4, 2026
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in patients with atherosclerotic cardiovascular and cerebrovascular diseases and erectile dysfunction
Trial Details
NCT Number NCT07311330
Lead Sponsor Beijing Inno Medicine Co., Ltd.
Conditions
(from sponsor)		 Atherosclerotic Cardiovascular Disease (ASCVD), Erectile Dysfunction
Related terms Atherosclerosis, Erectile Dysfunction
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov